NeuroDerm (NDRM) Stock Skyrockets to One-Year High After Encouraging Parkinson's Treatment Results

Posted: Published on December 31st, 2014

This post was added by Dr Simmons

NEW YORK (TheStreet) -- Shares ofNeuroDerm (NDRM) skyrocketed more than 65% to a 52-week high of $10.31 in morning trading Tuesday after the Israeli company announced encouraging results from a trial for a treatment of Parkinson's disease.

NeuroDerm announcedcontinuous, subcutaneous dosage of two of its proprietary liquid levodopa/carbidopa (LD/CD) product candidates, ND0612H and ND0612L, resulted in clinically significant plasma levadopa levels. The data indicates thatthe high dose version, ND0612H, meant for patients with severe Parkinson's disease, could be an effective therapy alternative to current treatments that require surgery.

"Maintaining consistent levodopa concentrations has been the most significant hurdle in Parkinson's disease therapy," said Sheila Oren, MD, NeuroDerm's Vice President of Clinical and Regulatory Affairs.

Exclusive Report: Jim Cramers Best Stocks for 2015

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

View post:
NeuroDerm (NDRM) Stock Skyrockets to One-Year High After Encouraging Parkinson's Treatment Results

Related Posts
This entry was posted in Parkinson's Treatment. Bookmark the permalink.

Comments are closed.